Treatment of therapy-refractory hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in cardiovascular high risk patients – effectivity and safety in clinical routine. (September 2016) - Hollstein, T.; Spira, D.; Buchmann, N.; El-Zidy Ibrahim, N.; Bobbert, T.; Steinhagen-Thiessen, E.; Kassner, U.